MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » EuroPCR 2014: St. Jude touts EnligHTN data amid renal denervation backlash

EuroPCR 2014: St. Jude touts EnligHTN data amid renal denervation backlash

By

EuroPCR 2014: St. Jude touts EnligHTN data amid renal denervation backlash

True to its word, medtech titan St. Jude Medical (NYSE:STJ) hasn’t given up on renal denervation as a potentially disruptive treatment for patients with hypertension, releasing new data today showing that its 2nd-generation EnligHTN device appeared safe and effective in preliminary data.

St. Jude investigators reported an average of 25 mmHg points of blood pressure reduction in the less than 40 patients followed for 6 months, numbers that would compare to taking 2 anti-hypertensive drugs per day. More than 80% of patients achieved a successful "response" to renal denervation, meaning a 10 mmHg reduction in blood pressure.

The findings aren’t likely to stir too much enthusiasm at this year’s EuroPCR meeting, where doctors have been more than wary of the procedure in the aftermath of Medtronic’s (NYSE:MDT) Symplicity HTN-3 results, which failed to show any meaningful benefit for renal denervation.

Some docs even took to Twitter to publicly scold medical device makers for advertising their renal denervation devices, saying that the industry is putting "marketing before science."

St. Jude’s trial, although touting positive results for the company’s technology, is the type of non-randomized, preliminary study that once generated significant (and perhaps undue) hype around Medtronic’s Symplicity technology. That hype turned into a harsh backlash (as predicted by Dr. Darrel Francis and reported by MassDevice) when the most robust studies to date of renal denervation missed vital endpoints for efficacy.

EuroPCR’s prolific Tweet-ers were generally silent about the EnligHTN news today, but yesterday’s outcry over Medtronic’s advertising of its Symplicity systems got the company’s attention.

Christ Hospital cardiac electrophysiology director Edward Schloss (@EJSMD) aimed this message yesterday at Medtronic:

And he got a response:

MassDevice insights: Will renal denervation for hypertension recover from Symplicity-3?
Take this two minute predictive intelligence survey to help determine where the market thinks renal denervation for hypertension is going.

 Covidien unveils 2-year outcomes for drug-coated Stellarex angioplasty balloon
Covidien (NYSE:COV) unveiled new 2-year clinical trial data for its Stellarex drug-coated angioplasty balloon from the company’s 1st-in-human ILLUMENATE study, reporting that the device hit endpoints for safety with 82.3% primary patency, 87.9% freedom from clinically-driven target lesion revascularization and no amputations or cardiovascular deaths at 24 months. 
Read more

 TAVI: JenaValve releases post-market results of valve in high-risk patients
JenaValve said that postmarket studies of its transcatheter aortic valve implantation registry data from its JUPITER study found that the company’s valves met endpoints for 30-day and long-term safety and effectiveness in high-risk patients with severe degenerative aortic valve disease.
Read more

 Biotronik touts Orsiro ‘hybrid’ stent
Biotronik says its Orsiro ‘hybrid’ drug-eluting stent showed high success rates in preliminary data from the company’s BIOFLOW-III open-label clinical evaluation of target lesion failure at 12 months.
Read more

 TAVI: Direct Flow’s valve "excellent" at 12 months
Direct Flow Medical published 12-month data from its DISCOVER CE Mark clinical trial, reporting a 90% survival rate, low rates of procedural complications and "excellent overall hemodynamic results."
Read more

 St. Jude’s FFR tech helps docs make better care decisions
St. Jude Medical reported that results from its POST-IT study of FFR-guided treatment of coronary disease found that doctors were able to provide more informed and more appropriate care to patients with with ischemia-producing narrowings.
Read more

In case you missed it

RSS From Medical Design & Outsourcing

  • Baxter, 3M, Abbott near the top of Newsweek’s most responsible companies list
    Several medtech, healthcare and life sciences companies, including big names like Abbott (NYSE:ABT), 3M (NYSE:MMM) and Baxter (NYSE:BAX), are among the 500 “most responsible,” according to Newsweek. The outlet published its “America’s Most Responsible Companies 2022” list, marking the third installment of the compilation (in partnership with Statista), this time expanded to include 500 of the largest public corporations around. Companies were judged with… […]
  • HHS reports 63-fold increase in telehealth use during pandemic
    A new study from the U.S. Department of Health and Human Services found a 63-fold increase in Medicare telehealth use during the COVID-19 pandemic. The report analyzed Medicare fee-for-service data from 2019 and 2020 and highlighted that people in urban areas were more likely to seek and use telehealth services than rural residents. In addition,… […]
  • Carlyle makes a significant investment in Resonetics
    Carlyle-managed funds have acquired a significant interest in medical device contract manufacturer Resonetics. Today’s announcement did not include the investment size, but the deal values Nashua, New Hampshire–based Resonetics at roughly  $2.25 billion. Carlyle joins existing investor GTCR as a meaningful shareholder in the company. Resonetics focuses on producing highly technical components for medical device… […]
  • Interpreting Pump Performance Curves
    Reading pump performance curves is crucial to proper pump selection. This piece reviews the creation and use of diaphragm pump performance curves to determine flow at given vacuum or pressure conditions. Included is a lesser-known method to interpolate pump performance when flow restrictions exist on both the inlet and outlet sides of the pump. Download… […]
  • BD elaborates on diversity and equity goals
    BD (NYSE:BDX) earlier this week outlined its efforts this year related to global inclusion, diversity and equity. Franklin Lakes, New Jersey-based BD released its 2021 Global Inclusion, Diversity and Equity (ID&E) Report, highlighting the progress it’s made in human health as part of its environmental, social and governance (ESG) strategy, according to a news release.… […]
  • How to protect medical devices from hidden cybersecurity risks
    Your software supply chain could be a cybersecurity risk. Here’s what you can do. Vince Arneja, GrammaTech The healthcare industry has been fighting a war on two fronts during the COVID-19 pandemic against the virus and an outbreak of cyberattacks. The Department of Health and Human Services says the sector reported a 9,851% increase in… […]
  • Integer completes $220M Oscor acquisition
    Integer Holdings (NYSE: ITGR) announced today that it has completed its purchase of Oscor — a deal that expands the capabilities of what was already one of the world’s largest medtech contract manufacturers. Integer said the acquisition would cost $220 million when it first announced its plans in October. Oscor is the creator and marketer… […]
  • Respira Labs seeks FDA clearance for its wearable lung monitor
    Respira Labs recently announced that it has developed a wearable device that continuously assesses lung function without the need for traditional pulmonary function tests. Mountain View, California-based Respira Labs designed its Sylvee wearable initially to assess chronic obstructive pulmonary disease, COVID-19 and asthma patients. It is embedded with speakers and microphones that measure the change… […]
  • Owen Mumford starts work on new production center in U.K.
    Owen Mumford this week announced that it has started building its new production facility in Witney, Oxfordshire in the U.K. Owen Mumford’s new Witney facility will stand as a production site for the company’s recently launched, next-generation auto-injector Aidaptus. The company has decades of experience creating its own drug delivery, blood sampling and rapid diagnostic… […]
  • FDA’s Woodcock reassures about COVID-19 tests, vaccines under Omicron
    Acting FDA Commissioner Dr. Janet Woodcock thinks many COVID-19 tests will continue to work with the new Omicron variant — with information coming soon on vaccine efficacy. In a statement posted yesterday, Woodcock said she thought the agency is well-positioned to work with companies to address the potential impact of viral mutations on COVID-19 tests,… […]
  • Traco Power launches THM 60WI DC-DC converters
    Traco Power today announced it has launched its THM 60WI series of quarter brick DC-DC converters. The Baar, Switzerlad-based company designed the DC-DC converters with ultra-wide input ranges and safety approvals for medical and industrial applications. Traco Power’s THM 60WI series of converters consists of 12 models with 9-75 or 18-75 Vin ranges with single… […]

Leave a Reply